The Imugene Limited (ASX: IMU) share price is leaping higher today on the back of news the immuno-oncology company has entered into a licensing agreement.

The agreement will see Imugene licensing the patents for a novel combination immunotherapy targeting cancer cells.

At the time of writing, the Imugene share price is trading 5.3% higher than yesterday’s close, with shares in the company swapping hands for 34.75 cents.

Let’s take a closer look at the announcement Imugene made this morning.

Cancer therapy licensing agreement

Imugene has entered into a licensing agreement with City of Hope, an independent cancer research and treatment centre. The technology under the license is an extension of chimeric antigen receptor (CAR) T cell cancer therapy.

According to Lymphoma Australia, CAR T cell therapy uses a person’s T cells, which are a type of white blood cell, to attack cancer cells. CAR T cell therapy makes a person’s white blood cells attracted to CD19 protein, which is found on the surface of some types of cancer cells. The white blood cells can then attack the cancer.

As solid tumours don’t naturally produce CD19, they can’t currently be treated with CAR T cell therapy.

Under the licensing agreement, Imugene will license City of Hope’s CD19 therapy. The therapy is a CAR T cell therapy using City of Hope’s oncolytic virus, onCARlytics.

OnCARlytics has so far been successful in making solid tumours produce the CD19 protein.

Imugene states that targeting solid cancers with T cell therapy is the technology’s “holy grail”, as current Federal Drug Administration (FDA) approved CD19 CAR T drugs only work to treat blood cancers.

The first clinical trial is expected to start next year. Within it, onCARlytics will be combined with CAR T therapy to target solid tumours.

The trial will test the safety and efficacy of the treatment combination in humans.

So far, researchers at City of Hope have been able to successfully use onCARlytics to produce CD19 in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cells. They have also successfully combined onCARlytics with CAR T cell therapy in mice studies. The findings included a significant number of mice being cured of cancer with prolonged protective anti-tumour immunity.

Commentary from management

Imugene’s managing director and CEO Leslie Chong commented on the therapy. She said:

The CAR T cell field currently only treats ~10% of all cancers such as blood or liquid tumours, whereas this technology has the potential to open up the solid tumour market.

Imugene share price snapshot

The Imugene share price is having a fantastic year so far on the ASX, with today’s news bringing its latest boost.

Currently, the Imugene share price has gained around 240% since the start of 2021. It’s also up a whopping 1,033% since this time last year.

The company has a market capitalisation of around $1.6 billion, with approximately 4.7 billion shares outstanding.

More reading

• Here’s why the Imugene (ASX:IMU) share price opened 8% higher today
• Why Corp Travel Management, Imugene, MoneyMe, & Syrah are pushing higher

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Imugene (ASX:IMU) share price is jumping 5% today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2SXXcst

The chief financial officer of formerly ASX-listed company Traditional Therapy Clinics Limited has been sentenced to 1 year and 10 months imprisonment for stock market manipulation.

The NSW District Court also ordered Zhonghan Wu to serve 2 years and 6 months of a community corrections order for fraud convictions.

The sentencing was the result of an Australian Securities and Investment Commission (ASIC) investigation into Traditional Therapy Clinics shares immediately after it listed on the ASX in 2015.

The initial public offering (IPO) had raised $15 million for the business, at 50 cents per share.

Trying to keep the shares above IPO price

Wu, who is also known as John, executed transactions through multiple broking accounts as soon as Traditional Therapy Clinics was listed on the bourse.

According to ASIC, he was trying to artificially keep the stock above the IPO price.

“Mr Wu carried out and attempted to carry out multiple share transactions in TTC shares using four different trading accounts. The trading had the effect of creating an artificial price for TTC shares on the Australian Securities Exchange (ASX),” the watchdog stated.

“When trades in one trading account were rejected for suspicious trading, Mr Wu would use another trading account to continue trading in TTC shares.”

Judge Mark Buscombe found Wu’s trading “undermined the integrity of the market”. The judge added that the executive knew his “brazen campaign of price manipulation” was “wrong and illegal”.

Traditional Therapy Clinics was delisted in 2018 after it went into administration.

Loan fraud on Commonwealth Bank

Wu’s sentencing to community corrections order was for pleading guilty to fraud on a separate matter.

ASIC alleged that in 2012 and 2015 Wu was granted loans from Commonwealth Bank of Australia (ASX: CBA) totalling $550,000.

The CFO was later found to have submitted “false and misleading” documents to the bank in support of his loan applications.

Wu, who is out on bail, was ordered to undergo an Intensive Correction Order assessment. The result will be considered in the NSW District Court on 2 July to determine the exact nature of his imprisonment.

More reading

• Leading brokers name 3 ASX shares to sell today
• Why the Commonwealth Bank (ASX:CBA) share price is in the spotlight today
• Is there more upside to the CBA (ASX:CBA) share price following recent results?
• Why I’m loving this ASX bank share at the moment: fundie
• ASX 200 Weekly Wrap: After record high, ASX dips on inflation fears

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Exec jailed for ASX share market manipulation appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3onXhkK

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company’s strategic update to FY22.

During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%.

Rhythm moves ahead with strategic plans

Investors appear to be pleased with the company’s progress to commercialise its cancer detection technology, ColoSTAT, driving Rhythm shares higher.

In its announcement, Rhythm highlighted a number of activities that it is moving forward to launch ColoSTAT into global markets.

The first of its listed strategic initiatives is to accelerate United States market entry for ColoSTAT. The company has incorporated a wholly-owned entity to cement its foothold in the country to carry operations out smoothly. The initial pathway stages to obtain market approval from the United States Food and Drug Administration (FDA) has already commenced.

In addition, Rhythm has expanded its platform by setting up an Australian entity to hold its technology within. The company validated initial data that its lead biomarker has a global market opportunity for cancer diagnostics.

Regulatory entry in both Europe (CE Mark) and Australia is advancing ahead of completion in its ColoSTAT Study 7. CE Mark filing is slated for late 2021, and the Australian Therapeutic Goods Administration (TGA) has begun the regulatory approval process.

Lastly, the company is looking at further market entry strategies in Europe, Australia, New Zealand, China, and broader Asia. Further updates in regards to this are expected to be released to the ASX in the coming months.

Notably, the company is targeting its first revenue for late 2022.

Comments from the CEO

Rhythm CEO, Mr. Glenn Gilbert commented:

Following the exceptional ColoSTAT performance results from Study 6 and the LRF algorithm enhancement work, this has given the company confidence to now accelerate the execution of our commercial strategy, focusing on our path to market activities.

ColoSTAT will transform the global mass-market cancer diagnostic market, with exciting and positive impacts at a social and economic level.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,000%. The company’s shares were trading at 6.3 cents in June before accelerating later that year.

It’s worth noting that the Rhythm share price is trading just below its all-time high of $1.675, reached in March.

More reading

• Rhythm (ASX:RHY) share price surges 10% on ColoSTAT results

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Rhythm (ASX:RHY) share price is soaring 8% today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3byP481

On Monday I looked at three ASX shares that brokers have given buy ratings to this week.

Unfortunately, not all shares are in favour with them right now. Three that have just been given sell ratings are listed below. Here’s why these brokers are bearish on these ASX shares:

Commonwealth Bank of Australia (ASX: CBA)

According to a note out of Goldman Sachs, its analysts have reiterated their sell rating and $80.26 price target on this banking giant’s shares. While Goldman acknowledges that CBA’s balance sheet is strong and it has a sector leading capital position and superior performance on volume growth, it doesn’t believe this justifies the 42% premium it is currently trading on versus peers. The Commonwealth Bank share price is trading $98.34 this morning.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)

A note out of UBS reveals that its analysts have retained their sell rating but increased their price target on this medical device company’s shares to NZ$24.80 (A$23.03). While a strong full year result for FY 2021 is expected later this month, UBS believes that its earnings will decline materially in FY 2022 due to lower pandemic-related sales. And although it expects its earnings to return to growth in FY 2023, it is only expected to be a modest increase. In light of this, it appears to believe that its shares are overvalued at the current level. The Fisher & Paykel Healthcare share price is fetching $31.14 today.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at Citi have retained their sell rating but lifted the price target on this wine company’s shares to $9.70. This follows Treasury Wine’s investor day event last week. The broker notes that the company intends to reallocate some of its Chinese portfolio to the United States in an effort to drive sustainable growth over the long term. And although its guidance for FY 2021 was ahead of expectations, the broker notes that its longer term growth targets are not. As a result, it doesn’t appear to be in a rush to make a change to its recommendation. Particularly given the execution risks with its restructure. The Treasury Wine share price is trading at $11.22.

More reading

• Why the Commonwealth Bank (ASX:CBA) share price is in the spotlight today
• Is there more upside to the CBA (ASX:CBA) share price following recent results?
• The latest ASX shares that top brokers have upgraded to “buy”
• Can China really crash the iron ore price?
• Why I’m loving this ASX bank share at the moment: fundie

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Leading brokers name 3 ASX shares to sell today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3wd55sf

The Woodside Petroleum Limited (ASX: WPL) share price has been a positive performer on Tuesday.

In morning trade, the energy producer’s shares are up over 1% to $22.77.

Why is the Woodside share price rising?

Investors have been buying Woodside’s shares following the release of an announcement this morning.

According to the release, Woodside has decided to exit its 50% non-operated participating interest in the proposed Kitimat LNG (KLNG) development in British Columbia, Canada.

Management notes that the exit will include the divestment or wind-up and restoration of assets, leases and agreements covering the 480 km Pacific Trail Pipeline route and the site for the proposed LNG facility at Bish Cove.

However, Woodside will retain a position in the Liard Basin upstream gas resource.

What now?

Woodside will work with Kitimat Joint Venture participant and operator Chevron Canada (Chevron) to protect value during the exit. Chevron also announced its plan to divest its 50% interest in KLNG in December 2019.

The exit will come at a cost. Management estimates that its decision to exit KLNG will impact FY 2021 net profit after tax by approximately US$40 million to US$60 million. Positively for shareholders, these costs will be excluded from underlying net profit for the purpose of calculating its dividend.

Management commentary

Woodside’s Acting CEO, Meg O’Neill, explained that exiting KLNG will allow the company to focus on successfully delivering higher value opportunities in Australia and Senegal.

She said: “Following Chevron’s decision to exit KLNG and subsequent decision in March 2021 to cease funding further feasibility work, Woodside undertook a comprehensive review of our options for the project and our wider development portfolio.”

“The Kitimat LNG proposal was designed to develop a new source of LNG to supply Asian markets in the latter part of this decade. However, we have decided to prioritise the allocation of capital to opportunities that will deliver nearer-term shareholder value.”

“Woodside is focused on working towards the targeted final investment decision for the Scarborough LNG development in Western Australia in the second half of 2021 and the continued successful execution of our Sangomar oil project offshore Senegal.”

“Retaining an upstream position in the prolific Liard Basin provides Woodside a low-cost option to investigate potential future natural gas, ammonia and hydrogen opportunities in British Columbia,” she concluded.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• ASX 200 Weekly Wrap: After record high, ASX dips on inflation fears
• 5 things to watch on the ASX 200 on Monday
• 5 things to watch on the ASX 200 on Friday
• 5 things to watch on the ASX 200 on Thursday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Woodside (ASX:WPL) share price is rising today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3eT5ytO

The Laybuy Group Holdings Ltd (ASX: LBY) share price won’t be going anywhere on Tuesday.

Laybuy announced a trading halt before market open in relation to a proposed capital raising. The company expects the trading halt to remain in place until Thursday 20 May, or when the announcement regarding the capital raising is released. 

Why is Laybuy raising capital? 

Despite the Laybuy share price plummeting more than 60% since its first day of listing, the company has outlined a number of growth initiatives to leverage its scalable platform and market opportunity. 

From a geographic perspective, this includes accelerating its growth in the United Kingdom market, testing its United States beta for ANZ and UK merchants to access US-based customers and potential M&A opportunities that may arise from industry consolidation.

The company’s fourth-quarter presentation noted that the “US market remains a long-term growth opportunity”. However, the company has yet to set foot in the world’s largest economy besides the testing of its US beta product. 

More recently, the company announced that it had appointed a general manager into the newly created role for the UK and Europe to drive continued growth. 

The UK represents a significant opportunity for value creation for the company, with a 504% surge in gross merchandise value from FY20 to FY21. 

Laybuy’s global growth strategy, new hires and technology investments likely come with a hefty price tag. In the 12 months to 31 March 2021, the company has delivered a net loss of $45 million with a remaining $15 million in cash and cash equivalents. 

The capital raising will likely be used to shore up its balance sheet to further drive key strategic initiatives and growth plans. 

Why the Laybuy share price is down 60% in 9 months

Prior to entering the trading halt, the Laybuy share price had shrivelled to just 68 cents from an initial public offering (IPO) price of $1.41 per share. On its first day of listing on 7 September 2020, the company’s shares even surged as high as $2.30 before closing at $2.05. 

Laybuy chose to list during a period in which the buy now, pay later (BNPL) hype had arguably died down. Smaller BNPL rivals such as Splitit Payments Ltd (ASX: SPT) and Openpay Group Ltd (ASX: OPY) provide good examples of the timing challenges Laybuy has faced. 

The share prices of both competitors peaked in late August/early September, coinciding with when Laybuy made its ASX debut. Both Splitit and Openpay have slumped a similar 60% since. 

So, the Laybuy share price isn’t alone in its selloff, with both local and BNPL behemoths such as Afterpay Ltd (ASX: APT) all facing heavy selling across the board. 

More reading

• Laybuy (ASX:LBY) share price slides despite key UK appointment
• Why is the Zip (ASX:Z1P) share price down 11% so far this month?
• The Afterpay (ASX:APT) share price breaks below $100
• Laybuy (ASX:LBY) share price slides despite ‘record Mania sales’
• Why the Afterpay (ASX:APT) share price is sliding 5%

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the Laybuy (ASX:LBY) share price frozen today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3flnzQy

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

If a new analysis of Amazon.com (NASDAQ: AMZN) proves accurate, the already-popular retail stock is poised to nearly double very soon. Brian Nowak, an analyst at ever-influential investment bank Morgan Stanley, issued a research note Monday in which he said that in a best-case scenario, the stock could hit $6,000 per share in 2023. That’s a whopping 83% above the present level.

Nowak bases his argument on the price/earnings to growth (PEG) rates of other top retailers and consumer goods staples companies, many of which hover around 3. In his words, “Bull Case Closer to Retailers/[consumer goods] Staples Implies [around] $5,000-$6,000 Share Price: AMZN currently trades at [around] 1.2 [times] ’22 on a PEG basis, a [roughly] 30% discount to its median tech peer group.”

Even for those who think that evaluation might be extreme, the prognosticator indicates that Amazon still has a long runway. “As shown, even valuing [Amazon] at a 1.7 [times] PEG (in line with mega cap tech) would imply a $4,500 share price as ’23 earnings come into view. But this PEG would still be a [roughly] 45% discount to [Walmart]…and we argue [Amazon] could warrant a higher PEG,” he wrote.

Nowak’s not-ideal-case $4,500 per share — his official price target on the shares — would still mean a significant upside of 38% on Amazon’s most recent closing stock price.

His analysis is a compelling one, as the disparity between the PEG levels is stark. It adds another bullish log in the fire that has been Amazon’s stock in recent years. 

Perhaps it’s resonating with investors. On Monday, Amazon stock rose by 1.5%, while the S&P 500 stock index fell by 0.3%.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• 3 explosive shares that defy PE ratios
• Has COVID-19 killed the ASX WAAAX shares?
• Here are the US shares ASX investors were buying last week
• Nasdaq slump: will ASX tech shares face selling pressure today?
• 1 number you might have missed from Amazon’s earnings

Eric Volkman has no position in any of the stocks mentioned. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Amazon and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Amazon could skyrocket 83% by 2023, analyst says appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3huYLby

The St Barbara Ltd (ASX: SBM) share price is under pressure on Tuesday morning.

At the time of writing, the gold miner’s shares are down 10% to $1.84.

Why is the St Barbara share price crashing lower?

Investors have been selling the company’s shares this morning following the release of an update on its guidance for FY 2021.

As you might have guessed from the St Barbara share price reaction, the company’s update has not been a good one.

According to the release, St Barbara’s Leonara and Simberi operations are not performing in line with expectations.

What is happening?

In respect to the Leonara operation, a change in mining contractor to Macmahon Holdings Limited (ASX: MAH) on 5 May has not gone as smoothly as hoped. This has been driven by issues with the recruitment of critical roles and experienced operators.

This means the Leonara operation is now forecast to produce 150,000 to 160,000 ounces of gold with an all-in sustaining cost (AISC) of between A$1,815 to A$1,950 per ounce.

As a comparison, its previous guidance was for 175,000 ounces with an AISC of A$1,590 to A$1,630 per ounce.

Things weren’t much better for its Simberi operation which continues to be impacted by ore variability, which is ultimately affecting gold recoveries. In addition to this, COVID-19 is impacting workforce availability and weighing on its operations.

As a result, it now expects Simberi production of 80,000 to 90,000 ounces in FY 2021 with an AISC of A$1,790 to A$2,030 per ounce. This compares to its previous guidance of 95,000 ounces with an AISC of A$1,720 to A$1,810 per ounce.

One positive is that its Atlantic Gold operation is performing in line with expectations and is on course to achieve its guidance.

FY 2021 consolidated guidance

The sum of the above, is consolidated production of between 330,000 and 360,000 ounces with an AISC of A$1,547 and A$1,695 per ounce in FY 2021. This compares to its previous guidance of 370,000 to 380,000 ounces with an AISC of between A$1,440 and A$1,520 per ounce.

The St Barbara share price is now down 25% since the start of the year.

More reading

• 5 things to watch on the ASX 200 on Friday
• 5 things to watch on the ASX 200 on Friday
• ASX 200 Weekly Wrap: Shares have average week but a great month
• These were the worst performing ASX 200 shares last week
• How the St Barbara (ASX:SBM) share price hit a 52-week low

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post St Barbara (ASX:SBM) share price crashes 10% on guidance downgrade appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2S4shKl

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the move today. This follows the biotechnology company’s announcement that it has inked a new lucrative deal.

At the time of writing, the Telix Pharmaceuticals share price is trading for $4.17, up 0.48%. 

What did Telix announce?

According to this morning’s release, Telix advised it has entered into an exclusive commercial distribution agreement with Eckert & Ziegler.

Founded in 1997, Berlin-based Eckert & Ziegler is one of the world’s largest providers of isotope technology for medical use. The company specialises in cancer therapy, industrial radiometry, and nuclear-medical imaging.

Under the deal, Telix’s prostate cancer imaging product, Illuccix, will be supplied to the German market through Eckert & Ziegler. This will occur once the expected marketing authorisation application has been approved by German health authorities. It is expected that the green light will be given sometime in later this year.

Comments from the CEO

Telix CEO Dr. Christian Behrenbruch commented:

We are pleased to have entered this commercial distribution agreement with Eckert & Ziegler so that, subject to German regulatory approval, we will together be able to bring this highly anticipated imaging agent to German patients living with prostate cancer as efficiently as possible.

Eckert & Ziegler executive member of the board, Dr Harald Hasselmann added:

This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 68,000 men diagnosed with prostate cancer each year in Germany.

Addressable market for prostate cancer in Germany

A published report from Globocan stated that prostate cancer was the most commonly diagnosed cancer across Germany in 2020. Roughly 68,000 cases were recorded last year. That is almost double the rate of lung cancer patients – around 38,000.

The findings also noted that prostate cancer caused the second most common deaths in men in Germany. Over 15,000 men died from the disease in 2020. Additionally, more than 290,000 German men are living with prostate cancer.

Telix share price summary

Telix shares have been an outstanding performer over the last 12 months, gaining close to 200% for shareholders.

Based on today’s prices, Telix presides a market capitalisation of roughly $1.1 billion, with approximately 281 million shares outstanding.

More reading

• Telix (ASX:TLX) share price on watch amid clinical trial news
• The Telix (ASX:TLX) share price is wobbling today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Telix (ASX:TLX) share price is rising this morning appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3wef0xP

Shares in Newcrest Mining Ltd (ASX: NCM) could be in focus this morning with news the company has vowed to go carbon neutral by 2050. The Newcrest share price closed yesterday’s trade at $28.35.

The commitment follows the gold miner’s previous emissions reduction target, which it made in 2019. Then, Newcrest pledged to reduce its greenhouse gas emissions by 30% by 2030.

Let’s take a closer look at today’s news from Newcrest Mining. 

Net-zero carbon emissions by 2050

Newcrest Mining announced it aims to reach net-zero carbon emissions across its operational scope 1 and scope 2 emissions by 2050.

Scope 1 emissions are those created by the company’s direct activities, such as running fleet vehicles or machinery. Scope 2 emissions are created alongside the electricity that powers the company’s activities.

Newcrest stated it’s also working to reduce its scope 3 emissions. Scope 3 emissions are those created downstream of a company’s business, during activities such as the transportation or further treatment of products. It will be interesting to watch how the Newcrest share price performs today as investors digest the company’s new commitments.

The gold miner also outlined the progress it’s made in reaching its target to reduce greenhouse emissions by 30% by 2030.

So far, it has created greenhouse gas management plans, which link achievements in emissions reductions to senior executive incentive payments. It’s also begun to measure greenhouse gas emissions across its value chain.

Finally, Newcrest has continued to implement the use of renewable energy – particularly from wind.

Newcrest also publishes a comprehensive sustainability report each year outlining its progress towards sustainability in its operations. 

Commentary from management

Newcrest managing director and CEO Sandeep Biswas commented on the company’s net-zero emissions goal, saying:

Given our experience with identifying and applying innovative technologies, Newcrest has the potential to be at the forefront of meeting the challenge of net zero carbon emissions by 2050. As an industry more broadly, we have the ingenuity, technology and capability to take on this challenge and reduce our carbon footprint. We are seeing the rapid evolution of a range of new technologies that will help reduce emissions going forward and Newcrest is well positioned to leverage this technology as the world moves towards a zero-carbon future.

Newcrest Mining share price snapshot

The Newcrest Mining share price has been a solid performer on the ASX so far this year. Newcrest shares have jumped by almost 10% since the start of 2021. Though, they are still trading 12.1% less than they were this time last year.

The gold miner has a market capitalisation of around $23 billion, with approximately 817 million shares outstanding.   

More reading

• ASX 200 Weekly Wrap: After record high, ASX dips on inflation fears
• 5 things to watch on the ASX 200 on Monday
• Why is the De Grey (ASX:DEG) share price plummeting today?
• Brokers name 3 ASX shares to buy now
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Newcrest (ASX:NCM) share price in focus with carbon neutrality pledge appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3eUPlEB